Mansi J L, Berger U, Wilson P, Shearer R, Coombes R C
Ludwig Institute for Cancer Research (London-St. George's Group), St. George's Hospital Medical School, St. George's Hospital, London, England.
J Urol. 1988 Mar;139(3):545-8. doi: 10.1016/s0022-5347(17)42516-x.
We used a mixture of antisera to prostatic specific acid phosphatase, prostatic specific antigen, epithelial membrane antigen and cytokeratin to examine multiple marrow aspirates from patients with local (15) and metastatic prostatic carcinoma (15), and benign prostatic hypertrophy (10). We found moderate to large numbers of tumor cells in the bone marrow of 11 of 15 (73 per cent) patients with known metastatic disease and small numbers of abnormal cells in 2 of 15 (13 per cent) patients with apparently local disease. No tumor cells were found in patients with benign prostatic hypertrophy, and only 2 patients with metastatic disease had tumor cells in the bone marrow when conventional hematomorphological preparations were examined. These findings suggest that immunocytochemistry can increase the detection rate of metastatic prostatic carcinoma cells. Further followup of larger numbers of patients with local carcinoma will reveal whether the presence of micrometastases denotes a poor prognosis.
我们使用了针对前列腺特异性酸性磷酸酶、前列腺特异性抗原、上皮膜抗原和细胞角蛋白的抗血清混合物，来检测15例局限性前列腺癌患者、15例转移性前列腺癌患者以及10例良性前列腺增生患者的多份骨髓穿刺样本。我们发现，在15例已知有转移疾病的患者中，有11例（73%）的骨髓中存在中等到大量肿瘤细胞；在15例明显为局限性疾病的患者中，有2例（13%）存在少量异常细胞。良性前列腺增生患者的骨髓中未发现肿瘤细胞，在检查传统血液形态学标本时，只有2例转移性疾病患者的骨髓中发现了肿瘤细胞。这些发现表明，免疫细胞化学可以提高转移性前列腺癌细胞的检测率。对更多局限性癌患者进行进一步随访，将揭示微转移的存在是否预示着预后不良。
